The Comparison of Ticagrelor and Clopidogrel on Graft Patency after Coronary Artery Bypass Graft Surgery

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900022390

Enrollment

Unknown

Registered

2019-04-09

Start date

2019-04-22

Completion date

Unknown

Last updated

2019-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease

Interventions

1:ticagrelor

2:clopidogrel

Eligibility

Sex/Gender

Male

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Patients with CABG indications.

Exclusion criteria

Exclusion criteria: 1) Contraindications to clopidogrel; 2) Contraindications to ticagrelor; 3) Unable to stop oral anticoagulant treatment; 4) Increased risk of bradycardia events; 5) Receive strong CYP3A inhibitor/inducer treatment at the same time; 6) Patients with renal insufficiency requiring dialysis; 7) Patients without CABG were finally treated.

Design outcomes

Primary

Measure	Time frame
Patency;MACE;	—

Secondary

Measure	Time frame
bleeding events;	—

Countries

China

Contacts

Public ContactGao Feng

dlmchcsd@126.com+86 18640889301

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026